TipRanks
Advertisement
Advertisement
JCR Pharmaceuticals Corrects FY2025 Results as Profit Rebounds and Dividend Held Steady
PremiumCompany AnnouncementsJCR Pharmaceuticals Corrects FY2025 Results as Profit Rebounds and Dividend Held Steady
3M ago
JCR Pharmaceuticals Corrects FY2024 Results as Weak Performance Prompts Closer Scrutiny
Premium
Company Announcements
JCR Pharmaceuticals Corrects FY2024 Results as Weak Performance Prompts Closer Scrutiny
3M ago
JCR Pharmaceuticals to Grant Restricted Treasury Shares as Long-Term Incentive
Premium
Company Announcements
JCR Pharmaceuticals to Grant Restricted Treasury Shares as Long-Term Incentive
3M ago
JCR Pharmaceuticals Corrects Interim Results but Confirms FY2025 Outlook and Dividend Plan
PremiumCompany AnnouncementsJCR Pharmaceuticals Corrects Interim Results but Confirms FY2025 Outlook and Dividend Plan
5M ago
JCR Pharmaceuticals Revises Past Financial Results After Accounting Error Review
Premium
Company Announcements
JCR Pharmaceuticals Revises Past Financial Results After Accounting Error Review
5M ago
JCR Pharmaceuticals Corrects Nine-Month FY2025 Earnings Disclosure
Premium
Company Announcements
JCR Pharmaceuticals Corrects Nine-Month FY2025 Earnings Disclosure
5M ago
JCR Pharmaceuticals Swings Back to Profit and Lifts Full-Year Outlook
PremiumCompany AnnouncementsJCR Pharmaceuticals Swings Back to Profit and Lifts Full-Year Outlook
8M ago
JCR Books ¥1.88 Billion Government Subsidy as Extraordinary Income for Q3 FY2025
Premium
Company Announcements
JCR Books ¥1.88 Billion Government Subsidy as Extraordinary Income for Q3 FY2025
8M ago
JCR Pharmaceuticals Issues FY2025 Q3 Results Briefing With Caution on Outlook
Premium
Company Announcements
JCR Pharmaceuticals Issues FY2025 Q3 Results Briefing With Caution on Outlook
8M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―